翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海心瑋醫療科技股份有限公司 (於中華人民共和國註冊成立的有限責任公司) 呈交日期： 2025年10月3日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06609 | 說明 | H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股 ...

Group 1 - The article reports on share buybacks conducted by various companies on October 2, 2025, with Tencent Holdings leading in both the number of shares repurchased and the total amount spent [1] - Tencent Holdings repurchased 812,000 shares for a total of 550 million, representing 0.725% of its total share capital for the year [2] - Other notable companies involved in the buyback include Hang Seng Bank, which repurchased 200,000 shares for 23.94 million, and Cloud Factory, which repurchased 2 million shares for 9.59 million [2] Group 2 - The total number of shares repurchased by Tencent Holdings year-to-date is 66.625 million [2] - Hang Seng Bank's cumulative repurchase for the year stands at 8.73 million shares [2] - Cloud Factory's cumulative repurchase for the year is 6.109 million shares, indicating a significant buyback activity [2]

智通财经APP讯，心玮医疗-B(06609)发布公告，于2025年10月2日斥资58.3万港元回购8700股股份。 ...

格隆汇10月2日丨心玮医疗-B(06609.HK)公告，10月2日耗资58.3万港元回购8700股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06609 | 說明 | H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出 ...

智通财经APP讯，心玮医疗-B(06609)公布，2025年9月30日耗资22.593万港元回购3450股股份。 ...

心玮医疗-B(06609)公布，2025年9月30日耗资22.593万港元回购3450股股份。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海心瑋醫療科技股份有限公司 (於中華人民共和國註冊成立的有限責任公司) 呈交日期： 2025年9月30日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06609 | 說明 | H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 ...

Investment Rating - The industry rating is "Overweight" [4] Core Insights - The Chinese neurointerventional medical device market is expected to grow from CNY 4.9 billion in 2019 to CNY 37.1 billion by 2030, with a compound annual growth rate (CAGR) of 20.2% from 2019 to 2030 [16][22] - The number of ischemic stroke treatment surgeries in China is projected to increase from 45,800 in 2019 to 881,300 by 2030, representing a CAGR of 30.8% [22] - The market for neurointerventional devices in China is growing at a faster rate compared to the U.S., with a surgical penetration rate of only 9.1% in 2020, compared to 62.3% in the U.S. [22][24] Summary by Sections 1. Market Outlook for Vascular Diseases - Neurovascular diseases are a leading cause of death in China, accounting for over 20% of total deaths in 2019, and the prevalence of peripheral vascular diseases is increasing due to aging [14] - The interventional treatment market is in an emerging stage in China, driven by increased health awareness, rising cardiovascular disease rates, and supportive government policies [14] 1.1 Neurovascular Disease Market Outlook - The neurointerventional medical device market in China is projected to grow significantly, with a market size increase from CNY 2.6 billion in 2015 to CNY 4.9 billion in 2019, and expected to reach CNY 37.1 billion by 2030 [16] - The number of neurointerventional surgeries is expected to rise from 46,200 in 2015 to 740,500 by 2026, with a CAGR of 28.9% [17] 1.1.1 Neurointerventional Market Outlook - The market for neurointerventional devices is expected to grow significantly, with a projected CAGR of 20.2% from 2019 to 2030 [16] 1.1.2 Ischemic Neurovascular Disease Market Outlook - The number of ischemic stroke cases in China is expected to rise from 2.8 million in 2015 to 5.8 million by 2030, with a CAGR of 5.0% [22] 1.1.3 Hemorrhagic Neurovascular Disease Market Outlook - The penetration rate for hemorrhagic stroke neurointerventional surgeries in China is expected to increase from 9.1% in 2020 to 31.7% by 2026 [24] 1.2 Peripheral Vascular Disease Surgery Market Outlook - The number of peripheral artery disease patients in China is projected to grow from 53.05 million in 2022 to 62.92 million by 2030 [30] - The number of peripheral vascular interventions is expected to increase from 178,000 in 2022 to 623,000 by 2030, with a CAGR of 13.7% from 2026 to 2030 [31] 1.2.1 Peripheral Artery Disease Market Outlook - The prevalence of peripheral artery disease is increasing, with a projected growth in patient numbers due to aging [29] 1.2.2 Peripheral Venous Market Outlook - The market for peripheral venous intervention devices in China is expected to grow from CNY 1.01 billion in 2021 to CNY 4.99 billion by 2030, with a CAGR of 19.5% [35] 2. Companies Related to Neurovascular Diseases - MicroPort NeuroScience (02172.HK) is a leading company in neurointerventional consumables in China [2] - Guichuang Tongqiao (02190.HK) focuses on peripheral and neurovascular intervention devices [2] - Sino Medical (688108.SH) covers key areas in cardiovascular and neurovascular interventions [2] - Xinwei Medical (06609.HK) provides comprehensive solutions for stroke treatment and prevention [2]

心玮医疗-B(06609)公布，2025年9月29日耗资约61.76万港元回购9700股股份。 ...